GTXI GTx Inc.

1.19
0  0%
Previous Close 1.19
Open 1.22
Price To Book 0.92
Market Cap 28621694
Shares 24,051,844
Volume 252,071
Short Ratio
Av. Daily Volume 2,023,629

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170131
  2. 8-K - Current report 181131527
  3. 8-K - Current report 181080589
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181017777
  5. 8-K - Current report 181014261

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2, 2009.
Toremifene
Reduce fractures in men with prostate cancer
Noted August 14, 2017 that trial will not continue due to insufficient clinical benefit response (CBR).
Enobosarm
Breast cancer - advanced AR+ TNBC
Phase 2 data released September 21, 2018 did not meet primary endpoint.
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2 updated open-label data presented May 18, 2018 at American Urological Association (AUA) Meeting.
Enobosarm - open label
Stress urinary incontinence (SUI)

Latest News

  1. Recent Analysis Shows Automatic Data Processing, GTx, Ionis Pharmaceuticals, TriNet Group, Ternium S.A, and UNIVERSAL INSURANCE HOLDINGS INC Market Influences — Renewed Outlook, Key Drivers of Growth
  2. Zacks.com featured highlights include: Guess?, GTX, NCI, EMCOR and Mitek
  3. What Overvaluation? 5 Stocks With Rising P/E Are Good Buys
  4. GTx: 3Q Earnings Snapshot
  5. GTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  6. Who makes what: Big bucks paid to Memphis' top company execs
  7. New Research Coverage Highlights Adesto Technologies, Pain Therapeutics, U.S. Global Investors, GTx, Columbus McKinnon, and Baytex Energy — Consolidated Revenues, Company Growth, and Expectations for 2018
  8. Today’s Research Reports on Stocks to Watch: GTx and TrovaGene
  9. Today’s Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics
  10. Why GTx, Tilray, and United Natural Foods Slumped Today
  11. Here's Why GTx, Inc. Dropped Over 92% Today
  12. GTx Inc. stock drops 94% premarket after phase 2 trial failure
  13. GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence
  14. Are Options Traders Betting on a Big Move in GTx (GTXI) Stock?
  15. GTx, Inc. to Participate in the Baird 2018 Global Healthcare Conference
  16. GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170131
  2. 8-K - Current report 181131527
  3. 8-K - Current report 181080589
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181017777
  5. 8-K - Current report 181014261
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 18864495
  7. 8-K - Current report 18846210
  8. 8-K - Current report 18838946
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18833083
  10. 8-K - Current report 18833049